Comprehensive Insights Provided into the Epidemiology Segments and Forecasts, the Future Growth Potential of Diagnosis Rate, Disease Progression, and Diagnostic GuidelinesDublin, Dec. 05, 2024 (GLOBE ...
AstraZeneca's IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the presentation of the Phase 3 ...
Based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo AstraZeneca's IMFINZI (durvalumab) has been approved in the US for the treatment of adult ...
Dr. Scott Tagawa presented ProstACT GLOBAL, a phase III study of best SOC with or without 177 Lu-DOTA-rosopatamab (TLX591) for patients with PSMA-expressing mCRPC who experienced disease progression ...